人EGF受体干扰序列-IL18融合基因构建及其表达产物结构预测  

Construction of human EGF-IL18 recombinant gene and structural predktkm of the fusion protein

作　　者：彭颖[1] 吕建新[1] 

机构地区：[1]温州医学院检验医学与公共卫生学院细胞与分子医学研究所,浙江温州325027

出　　处：《温州医学院学报》2003年第5期289-291,共3页Journal of Wenzhou Medical College

基　　金：浙江省医药卫生重点科技资助项目(No.2001ZD007);温州市科技发展计划资助项目(S2001A21)。

摘　　要：目的:构建带有EGF受体干扰序列的人IL-18融合基因并预测其表达产物的二级结构。方法:利用分子生物学技术,将人IL-18的成熟肽序列cDNA与EGF受体干扰序列cDNA融合,构建重组体EGF-IL18。应用蛋白质分析软件对融合基因翻译后在二级结构水平上的一些生物学特性加以预测。结果:测序表明融合基因序列与设计一致。其相应的氨基酸序列经软件分析,并与人IL-18的成熟肽单独的分析结果相比较,发现在二级结构水平几乎没有变化,融合过程未影响IL-18的活性。结论:该融合基因可进一步用于导向多肽EGF-IL8的基因工程。Objective:To construct the human EGF-IL18 recombinant gene and predict its secondary structure.Meth-ods:The cDNA of IL-18 mature peptide and EGF receptor interferential sequence were linked by using PCR cloning.The protein analysis software was utilized to predict the flexibility and hydrophilicity of fusion protein.Results:The recombinant gene construction was confirmed by DNA sequencing. Through the analysis of the software, it could be found that the secondary structure of IL-18 mature peptide has almost unchanged after fusion and remain its bioactivity. Conclusion:This recombinant gene can be used in the future genetic engineering to produce human EGF-IL18.

关 键 词：人 EGF受体干扰序列 ILl8 融合基因 表皮生长因子 EGF 基因工程 

分 类 号：R394[医药卫生—医学遗传学]